Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Chlorphen

    Chloramphenicol (Oral)
    Capsule 250 mg Allopathic Macrolides

    Indications

    Bacterial infections

    Indication detailsView
    Chloramphenicol is an antibiotic that is clinically useful for, and should be reserved for, serious infections caused by organisms susceptible to its antimicrobial effects when less potentially hazardous therapeutic agents are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present. In vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol, rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen, should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, and the efficacy of the various drugs in the infection
    Therapeutic classView
    Macrolides
    PharmacologyView
    In vitro, chloramphenicol exerts mainly a bacteriostatic effect on a wide range of Gram-negative and Gram positive bacteria and is active against rickettsiae, the lymphogranuloma-psittacosis group and Vibrio cholerae. It is particularly active against Salmonella typhi and Haemophilus influenzae. The mode of actions is through interference or inhibition of protein synthesis in intact cells and cell-free systems. Antagonism has been demonstrated in vitro between chloramphenicol, erythromycin, clindamycin and lincomycin. Chloramphenicol is rapidly absorbed from the GI tract. Chloramphenicol palmitate is hydrolyzed in the GI tract and is absorbed as free chloramphenicol.

    Following oral administration of a single one gram dose of chloramphenicol base to healthy adults, average peak plasma chloramphenicol concentrations of about 11 mcg/ml were attained with 1-3 hours. Cumulative dosing gave a peak of 18 mcg/ml after the fifth dose of one gram, every 6 hours. Mean serum levels were 8-14 mcg/ml over a 48 hour period.

    Most of the drug is excreted in the urine. Despite the small proportion of unchanged drug excreted in the urine, the concentration of free chloramphenicol in the urine is relatively high. From 8% to 12% of the antibiotic is excreted as free chloramphenicol. The remainder is excreted as inert metabolites, mainly glucuronate. Small amounts of active drug are found in bile and feces. Chloramphenicol diffuses rapidly, but its distribution is not uniform. Highest concentrations are found in liver and kidney, and lowest concentrations are found in brain and cerebrospinal fluid (CSF). Chloramphenicol enters CSF even in the absence of meningeal inflammation, appearing in concentrations about half of those found in the blood.
    DosageView
    Chloramphenicol, like other potent drugs, should be prescribed at recommended doses known to have therapeutic activity. Inhibition of the majority of sensitive organisms may be expected at concentrations of 5 to 20 mcg/ml. The desired concentration of active drug in serum should fall within this range over most of the treatment period. Dosage of 50 mg/kg/day divided into 4 doses at intervals of 6 hours will usually achieve and sustain levels of this order.

    Except in certain circumstances (e.g. premature infants and neonates and individuals with hepatic or renal impairment) lower doses may not achieve these concentrations. Close observation of the patient should be maintained and in the event of any adverse reactions, dosage should be reduced or the drug discontinued, if other factors in the clinical situation permit.

    Adults: should receive 50 mg/kg/day in divided doses [approximately one 250 mg capsule per each 4.5 kg (10 lbs) of body weight or one 500 mg capsule per each 9 kg (20 lbs) of body weight] in divided doses at 6 hour intervals. In exceptional cases, patients with infections due to moderately resistant organisms may require increased dosage up to 100 mg/kg/day to achieve serum levels inhibiting the pathogen, but these high doses should be decreased as soon as possible.

    Adults with impairment of hepatic or renal function, or both, may have reduced ability to metabolize and excrete the drug. In instances of impaired metabolic processes, dosages should be adjusted accordingly.

    Pediatric patients: Dosage of 50 mg/kg/day divided at 6 hour intervals is effective against most susceptible organisms. Severe infections (eg., bacteremia or meningitis), especially when adequate cerebrospinal fluid concentrations are desired, may require dosage up to 100 mg/kg/day; however, it is recommended that dosage be reduced to 50 mg/kg/day as soon as possible. Children with impaired hepatic or renal function may retain excessive amounts of the drug.

    Newborn infants: A total of 25 mg/kg/day in 4 equal doses at 6-hour intervals usually produces and maintains concentrations in serum and tissues adequate to control most infections for which the drug is indicated.
    ContraindicationsView
    Chloramphenicol is contraindicated in individuals with a history of hypersensitivity and/or toxic reaction to the product or its components. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, viral influenza, infections of the throat or as a prophylactic agent to prevent bacterial infections.
    PrecautionsView
    It is essential that adequate hematologic functions be closely monitored during treatment with the drug. While hematologic determinations may detect early peripheral hematologic changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such determinations cannot be relied on to detect bone marrow depression prior to development of aplastic anemia
    InteractionsView
    Chloramphenicol has been shown to retard the biotransformation of tolbutamide, phenytoin, and dicoumarol in man. Chloramphenicol should be used with caution if administered concomitantly with lincomycin, clindamycin, or erythromycin. In vitro experiments have demonstrated that binding sites for erythromycin, lincomycin, clindamycin and chloramphenicol overlap and competitive inhibition may occur. Rifampin therapy can reduce Chloramphenicol concentrations.
    Overdose effectsView
    Levels exceeding 25 mcg/ml are frequently considered toxic. Chloramphenicol toxicity can be evidenced by serious hemopoietic effects such as aplastic anemia, thrombocytopenia, leukopenia, as well as increasing serum iron levels, nausea, vomiting and diarrhea. In the case of serious overdosage, charcoal hemoperfusion may be effective in removing chloramphenicol from plasma. Exchange transfusion is of questionable value following massive overdosage, especially in neonates and infants.
    StorageView
    Store in a cool dry place. Keep bottle securely closed. Protect from light.

    Chlorphen

    Chloramphenicol + Lidocaine Hydrochloride
    Ear Drop 5%+1% Allopathic Aural Anti-bacterial preparations

    Indications

    Otic infections

    Indication detailsView
    Acute bacterial ear infections
    Therapeutic classView
    Aural Anti-bacterial preparations
    PharmacologyView
    Chloramphenicol inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.

    Lidocaine is an amide type local anaesth. It stabilises the neuronal membrane and inhibits Na ion movements, which are necessary for conduction of impulses. In the heart, lidocaine reduces depolarisation of the ventricles during diastole and automaticity in the His-Purkinje system. Duration of action potential and effective refractory period are also reduced.
    DosageView
    Otic/Aural Otitis externa: Instill 2-3 drops into the ear bid-tid.
    Side effectsView
    Ototoxicity.
    ContraindicationsView
    History of hypersensitivity or toxic reaction to the drug; Perforated ear drum. Herpes simplex and other virul conditions of the eye or ear, mycosis.
    PrecautionsView
    Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur.
    InteractionsView
    Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.

    Potentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
    Pregnancy & lactationView
    Pregnancy Category C & B. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

    Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

    Chlorphen

    Chloramphenicol (Ophthalmic)
    Ophthalmic Ointment 1% Allopathic Macrolides

    Indications

    Whipple’s disease

    Indication detailsView
    Chloramphenicol is indicated for the treatment of ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. Such as Staphylococcus aureus, Streptococcus pneumoniae, E.coli, H. influenzae, Klebsiella/Enterobacter spp, Moraxella lacunata, and Neisseria species.
    Therapeutic classView
    Ear Anti-Infectives & Antiseptics, Eye Anti-Infectives & Antiseptics, Macrolides
    PharmacologyView
    Chloramphenicol is a broad-spectrum bacteriostatic antibiotic which acts through the inhibition of bacterial protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes.
    DosageView
    Adult and Children: Instill 1 or 2 drops in the conjunctival sac 4-6 times per day for the first 72 hours and then every 4 hours thereafter. Treatment should be continued for approximately 7 days, but should not be continued for more than 3 weeks without re-evaluation by the physician.
    Side effectsView
    The systemic adverse reaction has not been observed within short-term topical use of Chloramphenicol. The most frequently reported adverse reactions have been burning, stinging, conjunctival hyperemia, blood dyscrasia, allergic or inflammatory reactions, vesicular and maculopapular dermatitis.
    ContraindicationsView
    It is contraindicated in individuals with a history of hypersensitivity to Chloramphenicol or any ingredients of the preparation.
    PrecautionsView
    Chloramphenicol ophthalmic solution should never be given for minor infections or for prophylaxis. Repeated course and prolonged treatment should be avoided. Blood dyscrasias (granulocytopenia, thrombocytopenia and moderate anaemia) may occur after prolonged ophthalmic use.
    InteractionsView
    Chymotrypsin may be inhibited if given simultaneously with Chloramphenicol.
    Pregnancy & lactationView
    Safety for use in pregnancy and lactation has not been established. Therefore, use only when considered essential by the physicians.
    Overdose effectsView
    Accidental ingestion of the medicine is unlikely to cause any toxicity due to low content of antibiotic.
    StorageView
    Store in a cool (between 2°C-8°C) and dry place, protect from light, keep out of reach of children. Do not touch the dropper tip to the surface since this may contaminate the solution. Do not use after 30 days of the first opening.

    Chlorpheniramine

    Chlorpheniramine Maleate
    Tablet 4 mg Allopathic Sedating Anti-histamine

    Indications

    Watery eye

    Indication detailsView
    Chlorpheniramine Maleate is indicated in the following indications-
    • Urticaria
    • Sensitivity reactions
    • Angioneurotic edema
    • Vasomotor rhinitis
    • Cough
    • Common cold
    • Motion sickness and
    • Other allergic conditions.
    Therapeutic classView
    Sedating Anti-histamine
    PharmacologyView
    Chlorpheniramine Maleate is an alkylamine antihistamine. It is one of the most potent histamine H1-receptor blocking agents which is used as a potent antihistamine. This generally causes less sedation than promethazine. Chlorpheniramine Maleate exerts its effects by blocking H1-receptor competitively.
    DosageView
    Adult- Usual adult dose is 4 mg every 4-6 hours, maximum 24 mg daily.

    Child-
    • 6-12 years: 2 mg every 4-6 hours, maximum 12 mg daily.
    • 2-5 years: 1 mg every 4-6 hours, maximum 6 mg daily.
    • 1-2 years: 1 mg twice daily.
    Below 1 year the use of Chlorpheniramine Maleate is not recommended.
    Side effectsView
    Chlorpheniramine is well-tolerated, but sometimes drowsiness, dizziness, muscular weakness, and gastrointestinal upset may occur.
    ContraindicationsView
    Chlorpheniramine is contraindicated in patients hypersensitive to this agent, in newborn or premature infants.
    PrecautionsView
    Chlorpheniramine should be used with caution in patients with glaucoma and prostatic hypertrophy. During therapy with chlorpheniramine, caution should be taken in driving vehicles and operating machinery.
    InteractionsView
    Chlorphenamine maleate has been reported to be incompatible with calcium chloride, kanamycin sulfate, noradrenaline acid tartrate, pentobarbital sodium, and meglumine adipiodone.
    Pregnancy & lactationView
    This drug should not be used in lactating mother and in pregnancy especially during the first trimester of pregnancy.
    Overdose effectsView
    CNS depression (including sedation, apnea, CV collapse), CNS stimulation (including insomnia, hallucination, tremors, convulsions), tinnitus, blurred vision, dizziness, ataxia, hypotension. Stimulation and atropine-like signs and symptoms (including dry mouth, fixed dilated pupils, flushing, hyperthermia, Gl symptoms) are more likely in children.
    StorageView
    Store in a cool (Below 25°C temperature) and dry place protected from light. Keep out of the reach of children.

    Cholcut

    Rosuvastatin
    Tablet 20 mg Allopathic Other Anti-anginal & Anti-ischaemic drugs

    Indications

    Stroke

    Indication detailsView
    Rosuvastatin is indicated in-
    • Heterozygous Hypercholesterolemia (Familial and Non familial)
    • Homozygous Hypercholesterolemia (Familial)
    • Mixed Dyslipidemia (Fredrickson Type IIa and IIb)
    • Primary prevention of cardiovascular disease
    Therapeutic classView
    Other Anti-anginal & Anti-ischaemic drugs, Statins
    PharmacologyView
    Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
    DosageView
    Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg

    HoFH: Starting dose 20 mg/day.

    Pediatric patients with HeFH: 5-10 mg/day for patients 8 to less than 10 years age, and 5-20 mg/day for patients 10 to 17 years of age.

    Pediatric patients with HoFH: 20 mg/day for patients 7 to 17 years of age.
    AdministrationView
    Rosuvastatin can be taken with or without food, at any time of day.
    Side effectsView
    Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to Rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea.
    ContraindicationsView
    Rosuvastatin is contraindicated if-
    • Known hypersensitivity to product components
    • Liver disease, which may include unexplained persistent elevations in hepatic transaminase levels
    • Pregnant women and women who may become pregnant
    • Nursing mothers
    PrecautionsView
    Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with use of 40 mg dose, advanced age (>65 year), hypothyroidism, renal impairment and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir or certain other lipid-lowering drugs. Patients should be advised to promptly report unexplained muscle pain, tenderness or weakness. Rosuvastatin can be discontinued if signs or symptoms appear.

    Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminases can occur.

    Liver enzymes should be monitored before and during treatment
    InteractionsView
    Remarkable drug interactions of Rosuvastatin are-
    • Cyclosporine: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be limited to 5 mg once daily.
    • Gemfibrosil: Combination should be avoided. If used together, Rosuvastatin dose should be limited to 10 mg once daily.
    • Lopinavir/Ritonavir or atazanavir/ritonavir: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be to 10 mg once daily.
    • Coumarin anticoagulants: Combination prolongs international normalized ratio (INR). Stable INR should be achieved prior to starting Rosuvastatin. INR should be monitored frequently until stable upon initiation or alteration of Rosuvastatin therapy.
    • Concomitant lipid-lowering therapies: Use with fibrates and niacin products may increase the risk of skeletal muscle effects.
    Pregnancy & lactationView
    The safety in pregnant women has not been established. It is not known whether Rosuvastatin is excreted in human milk or not.
    Pediatric usageView
    Use in children: The safety and effectiveness in pediatric patients have not been established.
    StorageView
    Keep below 30oC temperature, protected from light & moisture. Keep out of the reach of children.

    Cholcut

    Rosuvastatin
    Tablet 10 mg Allopathic Other Anti-anginal & Anti-ischaemic drugs

    Indications

    Stroke

    Indication detailsView
    Rosuvastatin is indicated in-
    • Heterozygous Hypercholesterolemia (Familial and Non familial)
    • Homozygous Hypercholesterolemia (Familial)
    • Mixed Dyslipidemia (Fredrickson Type IIa and IIb)
    • Primary prevention of cardiovascular disease
    Therapeutic classView
    Other Anti-anginal & Anti-ischaemic drugs, Statins
    PharmacologyView
    Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
    DosageView
    Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg

    HoFH: Starting dose 20 mg/day.

    Pediatric patients with HeFH: 5-10 mg/day for patients 8 to less than 10 years age, and 5-20 mg/day for patients 10 to 17 years of age.

    Pediatric patients with HoFH: 20 mg/day for patients 7 to 17 years of age.
    AdministrationView
    Rosuvastatin can be taken with or without food, at any time of day.
    Side effectsView
    Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to Rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea.
    ContraindicationsView
    Rosuvastatin is contraindicated if-
    • Known hypersensitivity to product components
    • Liver disease, which may include unexplained persistent elevations in hepatic transaminase levels
    • Pregnant women and women who may become pregnant
    • Nursing mothers
    PrecautionsView
    Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with use of 40 mg dose, advanced age (>65 year), hypothyroidism, renal impairment and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir or certain other lipid-lowering drugs. Patients should be advised to promptly report unexplained muscle pain, tenderness or weakness. Rosuvastatin can be discontinued if signs or symptoms appear.

    Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminases can occur.

    Liver enzymes should be monitored before and during treatment
    InteractionsView
    Remarkable drug interactions of Rosuvastatin are-
    • Cyclosporine: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be limited to 5 mg once daily.
    • Gemfibrosil: Combination should be avoided. If used together, Rosuvastatin dose should be limited to 10 mg once daily.
    • Lopinavir/Ritonavir or atazanavir/ritonavir: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be to 10 mg once daily.
    • Coumarin anticoagulants: Combination prolongs international normalized ratio (INR). Stable INR should be achieved prior to starting Rosuvastatin. INR should be monitored frequently until stable upon initiation or alteration of Rosuvastatin therapy.
    • Concomitant lipid-lowering therapies: Use with fibrates and niacin products may increase the risk of skeletal muscle effects.
    Pregnancy & lactationView
    The safety in pregnant women has not been established. It is not known whether Rosuvastatin is excreted in human milk or not.
    Pediatric usageView
    Use in children: The safety and effectiveness in pediatric patients have not been established.
    StorageView
    Keep below 30oC temperature, protected from light & moisture. Keep out of the reach of children.

    Cholcut

    Rosuvastatin
    Tablet 5 mg Allopathic Other Anti-anginal & Anti-ischaemic drugs

    Indications

    Stroke

    Indication detailsView
    Rosuvastatin is indicated in-
    • Heterozygous Hypercholesterolemia (Familial and Non familial)
    • Homozygous Hypercholesterolemia (Familial)
    • Mixed Dyslipidemia (Fredrickson Type IIa and IIb)
    • Primary prevention of cardiovascular disease
    Therapeutic classView
    Other Anti-anginal & Anti-ischaemic drugs, Statins
    PharmacologyView
    Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methyl glutaryl coenzyme A to mevalonate, a precursor of cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second, Rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
    DosageView
    Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg

    HoFH: Starting dose 20 mg/day.

    Pediatric patients with HeFH: 5-10 mg/day for patients 8 to less than 10 years age, and 5-20 mg/day for patients 10 to 17 years of age.

    Pediatric patients with HoFH: 20 mg/day for patients 7 to 17 years of age.
    AdministrationView
    Rosuvastatin can be taken with or without food, at any time of day.
    Side effectsView
    Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to Rosuvastatin were headache, myalgia, constipation, asthenia, abdominal pain and nausea.
    ContraindicationsView
    Rosuvastatin is contraindicated if-
    • Known hypersensitivity to product components
    • Liver disease, which may include unexplained persistent elevations in hepatic transaminase levels
    • Pregnant women and women who may become pregnant
    • Nursing mothers
    PrecautionsView
    Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with use of 40 mg dose, advanced age (>65 year), hypothyroidism, renal impairment and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir or certain other lipid-lowering drugs. Patients should be advised to promptly report unexplained muscle pain, tenderness or weakness. Rosuvastatin can be discontinued if signs or symptoms appear.

    Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminases can occur.

    Liver enzymes should be monitored before and during treatment
    InteractionsView
    Remarkable drug interactions of Rosuvastatin are-
    • Cyclosporine: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be limited to 5 mg once daily.
    • Gemfibrosil: Combination should be avoided. If used together, Rosuvastatin dose should be limited to 10 mg once daily.
    • Lopinavir/Ritonavir or atazanavir/ritonavir: Combination increases Rosuvastatin exposure. Rosuvastatin dose should be to 10 mg once daily.
    • Coumarin anticoagulants: Combination prolongs international normalized ratio (INR). Stable INR should be achieved prior to starting Rosuvastatin. INR should be monitored frequently until stable upon initiation or alteration of Rosuvastatin therapy.
    • Concomitant lipid-lowering therapies: Use with fibrates and niacin products may increase the risk of skeletal muscle effects.
    Pregnancy & lactationView
    The safety in pregnant women has not been established. It is not known whether Rosuvastatin is excreted in human milk or not.
    Pediatric usageView
    Use in children: The safety and effectiveness in pediatric patients have not been established.
    StorageView
    Keep below 30oC temperature, protected from light & moisture. Keep out of the reach of children.

    Cholenak

    Sodium Chloride + Potassium Chloride + Sodium Acetate
    IV Infusion 0.5%+0.1%+0.393% Allopathic Electrolytes preparations

    Indications

    Vomiting

    Indication detailsView
    Cholera, Diarrhea, Severe vomiting and fluid loss due to excessive sweating
    Therapeutic classView
    Electrolytes preparations
    DosageView
    The volume and rate of infusion of Cholera Saline depends upon the requirements of the patient and the judgment of the physician. It usually varies with age, weight and clinical condition of the patient.

    Cholera Fluid

    Cholera Saline
    IV Infusion Allopathic Intravenous fluid preparations

    Indications

    Vomiting

    Indication detailsView
    Cholera Saline contains different electrolytes which are usually depleted in various conditions e.g. diarrhoea, vomiting, profuse sweating etc. So, this saline is indicated in cholera, also in diarrhoea, vomiting, fluid loss, to replenish and restore the normal electrolyte balance of the body.
    Therapeutic classView
    Intravenous fluid preparations
    DosageView
    The volume and rate of infusion of Cholera Saline depends upon the requirements of the patient and the judgement of the physician. It usually varies with age, weight and clinical condition of the patient.
    AdministrationView
    Administration Procedure:
    • Check infusion set and infusion solution prior to use
    • Pull moderately to tear off the protective cover of the Eurohead
    • Hold lightly the Eurohead but not the bag
    • Open the flow regulator fully and hold the giving set on the top white area, but not the membrane venting region
    • Insert the spike of the administration set to the Eurohead and fit the connector of the administration set firmly to the needle
    • Gradually allow the fluid to flow down to the needle tip and close
    • Remove the protective cover of the needle
    • Locate the venipuncture site and clean the site with an antiseptic solution, and then insert the needle
    • Securely tape the puncture site
    • Securely tape the wings and tubing
    • Start infusion while adjusting drip speed
    Side effectsView
    • Severe burning, pain, or swelling around the IV needle;
    • Warmth, redness, oozing, or bleeding where the IV was placed;
    • fever, ongoing cough.
    PrecautionsView
    Since Cholera Saline contains different electrolytes, it should be infused with caution in patients where electrolyte imbalance may cause detrimental effects, e.g. in pregnancy, renal impairment, heart failure, pulmonary congestion, head injury etc. or in patients receiving potassium sparing diuretics.
    StorageView
    Should be stored at controlled room temperature.

    Cholera Saline

    Cholera Saline
    IV Infusion Allopathic Intravenous fluid preparations

    Indications

    Vomiting

    Indication detailsView
    Cholera Saline contains different electrolytes which are usually depleted in various conditions e.g. diarrhoea, vomiting, profuse sweating etc. So, this saline is indicated in cholera, also in diarrhoea, vomiting, fluid loss, to replenish and restore the normal electrolyte balance of the body.
    Therapeutic classView
    Intravenous fluid preparations
    DosageView
    The volume and rate of infusion of Cholera Saline depends upon the requirements of the patient and the judgement of the physician. It usually varies with age, weight and clinical condition of the patient.
    AdministrationView
    Administration Procedure:
    • Check infusion set and infusion solution prior to use
    • Pull moderately to tear off the protective cover of the Eurohead
    • Hold lightly the Eurohead but not the bag
    • Open the flow regulator fully and hold the giving set on the top white area, but not the membrane venting region
    • Insert the spike of the administration set to the Eurohead and fit the connector of the administration set firmly to the needle
    • Gradually allow the fluid to flow down to the needle tip and close
    • Remove the protective cover of the needle
    • Locate the venipuncture site and clean the site with an antiseptic solution, and then insert the needle
    • Securely tape the puncture site
    • Securely tape the wings and tubing
    • Start infusion while adjusting drip speed
    Side effectsView
    • Severe burning, pain, or swelling around the IV needle;
    • Warmth, redness, oozing, or bleeding where the IV was placed;
    • fever, ongoing cough.
    PrecautionsView
    Since Cholera Saline contains different electrolytes, it should be infused with caution in patients where electrolyte imbalance may cause detrimental effects, e.g. in pregnancy, renal impairment, heart failure, pulmonary congestion, head injury etc. or in patients receiving potassium sparing diuretics.
    StorageView
    Should be stored at controlled room temperature.

    Cholvax

    Oral Cholera Vaccine
    Oral Suspension 1.5 ml/vial Allopathic Vaccines, Anti-sera & Immunoglobulin

    Indications

    Cholera

    Indication detailsView
    Oral Cholera Vaccine is indicated for active immunization against Vibrio cholerae. The vaccine can be administered to anyone above the age of 1 year. Data for the safety and efficacy of the vaccine in infants (less than 1 year of age) is not available. The earliest onset of protection can be expected 7-10 days after the completion of the primary series of the vaccine. Efficacy against Vibrio cholerae serogroup O139 was not demonstrated.
    Therapeutic classView
    Vaccines, Anti-sera & Immunoglobulin
    DosageView
    The recommended dose of the vaccine (1.5 ml) is to be administered orally. The primary immunization schedule consists of two doses given at an interval of at least two weeks. Cholera vaccine should not be administered parenterally (intramuscular, subcutaneous or intravenously). The vaccine is only recommended for oral administration.

    Method of administration: The vaccine is presented as a suspension. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient. The vaccine administration may be optionally followed by water to facilitate ingestion, if needed. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient. The vaccine should not be administered parenterally (intramuscular, subcutaneous or intravenously). The vaccine is only recommended for oral administration.
    Side effectsView
    The following adverse events are known to occur with cholera vaccine use. Acute gastroenteritis, diarrhea, fever, vomiting, abdominal pain, itching, rash, nausea, weakness, cough, vertigo, dryness of mouth, oral ulcer (rare), sore throat (rare) and yellowing of urine (rare). It has been observed that the incidence of adverse events is less after the second dose as compared to the first.
    ContraindicationsView
    Cholera vaccine should not be administered to subjects with either known hypersensitivity to any component of vaccine, or having shown signs of hypersensitivity after previous administration of the vaccine. Formaldehyde is used during the manufacturing process and trace amounts may be present in the final product. Caution should be taken in subjects with known hypersensitivity to formaldehyde. CVV V.N. 02 TM As with other vaccines, immunization with the cholera vaccine should be delayed in the presence of any acute illness, including acute gastrointestinal illness or acute febrile illness. A minor illness such as mild upper respiratory tract infection is not a reason to postpone immunization
    PrecautionsView
    Vaccination should be provided by a review of the medical history (especilly with regard to previous vaccination & possible occurrence of the undesirable events) and a clinical examination. As with any vaccine immunization with the cholera vaccine may not protect 100% susceptible individuals. This vaccine is also not a substitute for therapy in case of individuals suspected to be suffering from cholera or showing signs and symptoms of an acute episode of gastro intestinal disease or acute watery diarrhea. Immunocompromised persons (subsequent to a disease or immunosuppressive therapy) may not obtain the expected immune response after vaccination with the cholera vaccine. If possible, in the opinion of the medical practitioner, due consideration should be given to postpone vaccination until after the completion of the immunosuppressive treatment. As with all vaccines, appropriate medical treatment should always be available in case of a rare event of anaphylactic reactions following the administration of the vaccine. For this reason, it is recommended that the vaccinee should remain under medical supervision for at least 30 minutes after vaccination.
    Pregnancy & lactationView
    No specific clinical studies have been performed to evaluate the safety and immunogenicity of cholera vaccine in pregnant women and for the fetus. However, administration of cholera vaccine to pregnant women and nursing mother may be considered after careful evaluation of the benefits and risks in case of a medical emergency or an epidemic.
    StorageView
    Keep out of the reach and sight of children. Store at +2 ºC to +8 ºC. Transportation should also be at +2 ºC to +8 ºC. Do not freeze. Discard vaccine if frozen. Protect from light.

    Choriofactor

    Human Chorionic Gonadotrophin
    IM Injection 5000 IU/vial Allopathic Female Sex hormones

    Indications

    Male Hypogonadotropic Hypogonadism

    Indication detailsView
    In the female:
    • Ovulation induction in infertility due to anovulation or impaired follicle-ripening.
    • Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (ART).
    • Luteal phase support.
    • Threatened and habitual abortion
    In the male:
    • Hypogonadotropic hypogonadism (also cases of idiopathic dysspermias have shown a positive response to gonadotropins).
    • Delayed puberty associated with insufficient gonadotropic pituitary function.
    • Cryptorchidism, (not due to anatomical obstruction)
    • Used to treat oligospermia
    Therapeutic classView
    Female Sex hormones
    PharmacologyView
    Pharmacodynamic Properties: Highly Purified Human Chorionic Gonadotrophin has LH activity. LH is indispensable in normal female and male gamete growth and maturation, and gonadal steroid production.
    • In the female: Human Chorionic Gonadotrophin is given as a substitute for the endogenous mid-cycle LH surge to induce the final phase of follicular maturation, leading to ovulation. Human Chorionic Gonadotrophin  is also given as a substitute for endogenous LH during the luteal phase.
    • In the male: Human Chorionic Gonadotrophin is given to stimulate Leydig cells to promote the production of testosterone.
    Pharmacokinetic Properties: Maximal Human Chorionic Gonadotrophin  plasma levels will be reached approximately six hours after a single injection of Human Chorionic Gonadotrophin . Human Chorionic Gonadotrophin  is for approximately 80 percent metabolized, predominantly in the kidneys. Following intramuscular injection (IM) the apparent elimination half-life of Human Chorionic Gonadotrophin  is about 2 days. On basis of the recommended dose regimens and elimination half-life, accumulation does not occur.
    DosageView
    After addition of the solvent to the freeze-dried substance, the reconstituted Human Menopausal Gonadotrophin solution should be slowly administered intramuscularly.

    In the female: Ovulation induction and preparation of follicles for puncture: Usually, one injection of 5000- 10000IU Human Menopausal Gonadotrophin to complete treatment with an FSH-containing preparation.

    Luteal phase support: Two repeat injections of 2500 to 5000IU. Each may be given within nine days following ovulation or embryo transfer (for example on day 3, 6 and 9 after ovulation induction).

    Threatened & habitual abortion:  5000IU Human Menopausal Gonadotrophin will be given as  deep intramuscular injection twice weekly from the time of diagnosis (all before the 7th week of gestation)

    In the male: Hypogonadotropic hypogonadism: 2500 to 5000 IU Human Menopausal Gonadotrophin, two times per week. If the main complaint is sterility, additional doses of an FSH-containing (50IU FSH) are to be administered daily or two to three times a week. This treatment should be continued for at least three months before any improvement in spermatogenesis can be expected. During this treatment testosterone replacement therapy should be suspended. Once achieved, the improvement may in some cases be maintained by Human Menopausal Gonadotrophin alone.
    Side effectsView
    Allergic reactions have occasionally been reported with the use of urinary gonadotrophin preparations. These mostly involve local reactions such as pain and rash at the injection site, and generalized reactions such as rash and fever.

    In the female: Unwanted ovarian hyperstimulation syndrome. Which is Characteristic symptoms of unwanted ovarian hyperstimulation and the ovarian hyperstimulation syndrome are  included under 'Special warnings and special precautions for use'.

    In the Male: Water and sodium retention is occasionally seen after administration of high dosages; this is regarded as a result of excessive androgen production. Treatment with Human Chorionic Gonadotrophin  leads to increased androgen production.

    Therefore: Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be kept under close medical supervision, since aggravation or recurrence may occasionally be induced as a result of increased androgen production. Human Chorionic Gonadotrophin should be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development. Skeletal maturation should be monitored regularly.
    ContraindicationsView
    Known or suspected androgen-dependent tumours, such as prostatic carcinoma or breast carcinoma in the male.
    PrecautionsView
    In pregnancies occurring after induction of ovulation with gonadotropic preparations, there is an increased risk of multiplets birth. Unwanted ovarianhyperstimulation: In patients treated for infertility due to anovulation or impaired follicular ripening, the prior administration of an FSH containing preparation may lead to unwanted ovarian hyperstimulation. Therefore ultrasonic assessment of follicular development and determinations nations of estrogen levels should be performed prior to FSH-treatment and at regular intervals during FSH-treatment. Estrogen levels may rise very rapidly, e.g. more than a daily doubling for two or three consecutive days, and possibly reach excessively high values. If this unwanted ovarian hyperstimulation occurs (i.e. not as part of a treatment preparing for IVF/ET or GIFT/ZIFT), the administration of the FSH-containing preparation should be discontinued immediately. In that case Human Chorionic Gonadotrophin must not be given, because the administration of an LH-active gonadotrophin at this stage may induce, in addition to multiple ovulations, the ovarian hyperstimulation syndrome. This warning is particularly important with respect to patients with polycystic ovarian disease. Clinical symptoms of mild ovarian hyperstimulation syndrome are gastro-intestinal problems (pain, nausea, diarrhoea), painful breasts, and mild to moderate enlargement of ovaries and ovarian cysts. In rare cases severe ovarian hyperstimulation syndrome occurs, which may be life-threatening. This is characterized by large ovarian cysts (prone to rupture), ascites, often hydrothorax and occasionally
    InteractionsView
    No interactions of clinical relevance are known.
    Pregnancy & lactationView
    Pregnancy Category X. Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

    Use in lactation: It must not be used during lactation
    Pediatric usageView
    Pediatric Use: Induction of androgen secretion by HCG may induce precocious puberty in pediatric patients treated for cryptorchidism. Therapy should be discontinued if signs of precocious puberty occur.

    Geriatric Use: Clinical studies of Chorionic gonadotropin for injection did not include subjects aged 65 and over.
    Overdose effectsView
    The acute toxicity of urinary gonadotropin preparations has been shown to be very low. There are no symptoms of an acute parenteral overdose known in humans.
    StorageView
    There are two options:
    • Store at 2°C-8°C (in refrigerator). Do not freeze.
    • Store below 25°C for a single period of not more than 3 months.
    Protect from light & keep in dry place.

    Chrocee

    Ribavirin
    Capsule 200 mg Allopathic Hepatic viral infections (Hepatitis C)

    Indications

    Chronic hepatitis C

    Indication detailsView
    Ribavirin is indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with other antiviral drugs in patients with compensated liver disease not previously treated with interferon alpha and in adult CHC patients coinfected with HIV. Ribavirin should not be used alone.
    Therapeutic classView
    Hepatic viral infections (Hepatitis C)
    PharmacologyView
    Ribavirin is a synthetic nucleoside which has inhibitory action against respiratory syncytial virus, influenza virus and herpes simplex virus. The mechanism of action is not clear. It may act at several sites including cellular enzymes to interfere with viral nucleic acid synthesis. The mono- and triphosphate derivatives are known to be responsible for the antiviral action of the compound.
    DosageView
    The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. After 24 weeks of treatment virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV RNA below the limit of detection of the assay by 24 weeks. There are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population. In patients who relapse following interferon therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient populations.

    Ribavirin + Interferon: Genotype Ribavirin Daily Interferon alpha-2a Duration or interferon alpha-2b.
    • All <75 kg: (400+600) mg 3 MIU 3 times weekly 48 weeks Genotypes subcutaneously (Genotype1&4)
    • >75 kg: (600+600) mg 24 weeks (Genotype2&3)
    Ribavirin + Peg-Interferon: Genotype Ribavirin Daily Peg-Interferon alpha-2a Duration or Peg-interferon alpha-2b:
    • 1 & 4 < 75 kg: (400+600) mg 180 gm once weekly 48 weeks
    • > 75 kg: (600+600) mg subcutaneously 2 & 3 (400+400) mg 24 weeks
    Ribavirin may be administered without regard to food, but should be administered in a consistent manner. Drink plenty of water while being treated with this medication; drinking water will decrease the risk of serious side effects.
    Side effectsView
    The most common adverse reactions in adults receiving combination therapy are psychiatric and central nervous system effects, severe ocular disorder, dental and periodontal disorders & growth inhibition in children and adolescents that may be irreversible in some patients. The most common adverse reactions in pediatric subjects were similar to those seen in adults.
    ContraindicationsView
    Women who are pregnant. Ribavirin may cause fetal harm when administered to a pregnant woman. Ribavirin is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia). In combination with didanosine. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.
    PrecautionsView
    Birth defects and fetal death with ribavirin: Do not use in pregnancy and for 6 months after treatment. Patients must have a negative pregnancy test prior to therapy, use at least 2 forms of contraception and undergo monthly pregnancy tests. For a male patient, it is very important for his female partner to avoid becoming pregnant during treatment and during the 7 months after treatment and do not have sex with a pregnant women.
    InteractionsView
    Nucleoside reverse transcriptase inhibitors or reduce dose or discontinue interferon, ribavirin or both with worsening toxicities

    Azathioprine: Concomitant use of azathioprine with ribavirin has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity.
    Pregnancy & lactationView
    Pregnancy Category X. Ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the drug dose. Survival of fetuses and offspring was reduced.

    Nursing Mothers: It is not known whether Ribavirin is excreted in human milk. Because many drugs are excreted in human milk and to avoid any potential for serious adverse reactions in nursing infants from ribavirin, a decision should be made either to discontinue nursing or therapy with Ribavirin, based on the importance of the therapy to the mother.
    Pediatric usageView
    Pediatric Use: Safety and effectiveness of Ribavirin in combination with Peginterferon has not been established in pediatric patients below the age of 3 years.

    Geriatric Use: The risk of toxic reactions to this drug may be greater in patients with impaired renal function. The dose of Ribavirin should be reduced in patients with creatinine clearance less than or equal to 50 ml/min; and the dose of Interferon should be reduced in patients with creatinine clearance less than 30 ml/min.
    StorageView
    Keep out of the reach of children. Keep in a cool & dry place. Protect from light.

    Chuben DS

    Albendazole
    Chewable Tablet 400 mg Allopathic Anthelmintic

    Indications

    Worm infections

    Indication detailsView
    Albendazole is indicated in single and mixed infestations of-
    • Hookworm (Ancylostoma, Necator)
    • Roundworm (Ascaris)
    • Threadworm (Enterobius)
    • Whipworm (Trichuris)
    • Strongyloides
    • Tapeworm
    • Opisthorchi
    • Hydatid.
    Therapeutic classView
    Anthelmintic
    PharmacologyView
    Albendazole is a broad spectrum anthelmintic. Albendazole exhibits vermicidal, ovicidal and larvicidal activities. The drug is thought to exert its anthelmintic effect by blocking glucose uptake in the susceptible helminths, thereby depleting the energy level until it becomes inadequate for survival. Immobilization is followed by the parasite. These events may be a consequence of the binding and subsequent inhibition of parasite tubulin polymerization by Albendazole and its metabolites, although the drug also binds to human tubulin. Albendazole is extensively metabolized, probably in the liver. Albendazole is poorly absorbed from the gastrointestinal tract but rapidly undergoes extensive first-pass metabolism. The principal metabolite albendazole sulphoxide has anthelmintic activity and a plasma half-life of about 8.5 hrs. It is excreted in the urine together with other metabolites.
    DosageView
    Adults & children over 2 years:
    • 400 mg (1 tablet or 10 ml suspension) as a single dose in cases of Enterobius vermicularis, Trichuris trichiura, Ascaris lumbricoides, Ancylostoma duodenale and Necator americanus.
    • In cases of strongyloidiasis or taeniasis, 400 mg (1 tablet or 10 ml suspension) daily should be given for 3 consecutive days. If the patient is not cured on follow-up after three weeks, a second course of treatment is indicated. 
    Children of 1-2 years: Recommended dose is a single dose of 200 mg (5 ml suspension).

    Children under 1 year: Not recommended.

    In Hydatid disease (Echinococcosis):
    • Albendazole is given by mouth with meals in a dose of 400 mg twice daily for 28 days for patients weighing over 60 kg.
    • A dose of 15 mg/kg body weight daily in two divided doses (to a maximum total daily dose of 800 mg) is used for patients weighing less than 60 kg.
    • For cystic echinococcosis, the 28 days course may be repeated after 14 days without treatment, to a total of 3 treatment cycles.
    • For alveolar echinococcosis, cycles of 28 days of treatment followed by 14 days without treatment, may need to continue for months or years.
    • In giardiasis, 400 mg (1 tablet or 10 ml suspension) once daily for five days is used.
    Side effectsView
    Gastrointestinal disturbances, headache, dizziness, changes in liver enzymes, rarely reversible alopecia; rash, fever, blood disorders including leucopenia and pancytopenia reported; allergic shock if cyst leakage; convulsion and meningism in cerebral disease.
    ContraindicationsView
    Neonates: Albendazole is not normally used in neonates.

    Children: Reduction of the dose from 400 mg to 200 mg may be indicated in children weighing less than 10 kg but there are no grounds for a general reduction in dosage to children.

    Pregnant woman: Albendazole should not be given during pregnancy or women thought to be pregnant. No information is available on placental transfer.

    Concurrent disease: There is no evidence to suggest that dose should be altered in renal, hepatic or cardiac failure.
    PrecautionsView
    Blood counts and liver function tests before treatment and twice during each cycle; breastfeeding; exclude pregnancy before starting treatment. Albendazole should only be used in the treatment of Echinococcosis if there is constant medical supervision with regular monitoring of serum-transaminase concentrations and of leucocyte and platelet counts
    InteractionsView
    No interaction involving Albendazole, either pharmacodynamic or pharmacokinetic, has been reported.
    Pregnancy & lactationView
    US FDA Pregnancy category of Albendazole is C. So, Albendazole should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Ciafil

    Tadalafil
    Tablet 20 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Ciafil

    Tadalafil
    Tablet 10 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Cialix

    Tadalafil
    Tablet 20 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Cialix

    Tadalafil
    Tablet 5 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Cialix

    Tadalafil
    Tablet 10 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Ciaton

    Tadalafil
    Tablet 5 mg Allopathic Drugs for Erectile Dysfunction

    Indications

    Pulmonary arterial hypertension

    Indication detailsView
    Tadalafil is indicated in-
    • Erectile Dysfunction (ED)
    • Benign Prostatic Hyperplasia (BPH)
    • Both Erectile Dysfunction and signs and symptoms of Benign Prostatic Hyperplasia
    Therapeutic classView
    Drugs for Erectile Dysfunction
    PharmacologyView
    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Inhibition of PDE5 increases cGMP in smooth muscle cells. cGMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, causing penile erection. PDE5 also is present in smooth muscles of the prostate and bladder wall. Inhibiting PDE5 increases cGMP concentrations leading to relaxation of smooth muscle in the prostate and bladder. Smooth muscle relaxation may improve blood flow to the urinary tract and widen the opening of the bladder neck, resulting in improved voiding.
    DosageView

    Erectile Dysfunction: For most patients the recommended starting dose is 10 mg. The dose may be increased to 20 mg or decreased to 5 mg based on requirement. The maximum dosing frequency is once daily. Tadalafil is effective for up to 36 hours.

    Benign prostatic hyperplasia: The recommended dose is 5 mg taken at the same time every day.

    Combined Erectile Dysfunction and Benign prostatic hyperplasia: The recommended dose is 5 mg at the same time every day.

    Side effectsView
    Headache, Dyspepsia, Back pain, Myalgia, Nasal pharyngitis, Nasal congestion are common side effects. Change in Color Vision, Sudden vision loss, Hearing loss, Stevens-Johnson Syndrome, Exfoliative dermatitis, Angina, Stroke, Myocardial infarction, Severe hypotension, Tachycardia may also occur rarely.
    ContraindicationsView
    • Use of Nitrates (for example, Nitroglycerine, Isosorbide): may increase hypotensive effects of Nitrates
    • Hypersensitivity reactions to Tadalafil
    PrecautionsView
    Angina, renal impairment, hepatic impairment, bleeding concomitant with Nitrates, Alpha Blockers, Alcohol, CYP3A4 Inhibitors (for example, Ritonavir, Ketoconazole, Itraconazole), other PDE5 inhibitors precaution should be taken in all these conditions.
    InteractionsView
    May interact with Nitrates for example, Isosorbide, Nitroglycerin, Alpha adrenergic blockers, Antihypertensives, Alcohol, Antacids (magnesuim hydroxide/aluminum hydroxide), Ketoconazole, Ritonavir, Erythromycin, Itraconazole, Grapefruit juice, other HIV protease inhibitors, Rifampin, Carbamazepine, Phenytoin & Phenobarbital.
    Pregnancy & lactationView
    Tadalafil has been assigned to pregnancy category B by the USFDA. Tadalafil is only recommended for use during pregnancy when benefit outweighs risk. There are no data on the excretion of Tadalafil in human milk. Caution should be used when administering tadalafil to nursing women.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.